Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 19:16
04/05/21
04/05
19:16
04/05/21
19:16
ICAD

iCAD

$19.96 /

+0.04 (+0.20%)

, ILMN

Illumina

$384.41 /

-0.72 (-0.19%)

, SPNE

SeaSpine

$17.93 /

+0.23 (+1.30%)

, DCT

Duck Creek Technologies

$44.50 /

-0.5 (-1.11%)

, GBOX

GreenBox

$15.36 /

+1.47 (+10.58%)

, OPNT

Opiant Pharmaceuticals

$11.15 /

+0.49 (+4.60%)

, MRVI

Maravai Lifesciences

$34.59 /

+0.4 (+1.17%)

, PSX

Phillips 66

$82.06 /

-1.08 (-1.30%)

, ARES

Ares Management

$59.12 /

+1.59 (+2.76%)

, TPTX

Turning Point Therapeutics

$89.91 /

-0.7 (-0.77%)

, UCTT

Ultra Clean

$64.92 /

+1.37 (+2.16%)

, USAT

USA Technologies

$12.77 /

+0.76 (+6.33%)

Check out this evening's…

ShowHide Related Items >><<
USAT USA Technologies
$12.77 /

+0.76 (+6.33%)

UCTT Ultra Clean
$64.92 /

+1.37 (+2.16%)

TPTX Turning Point Therapeutics
$89.91 /

-0.7 (-0.77%)

SPNE SeaSpine
$17.93 /

+0.23 (+1.30%)

PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

OPNT Opiant Pharmaceuticals
$11.15 /

+0.49 (+4.60%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

ICAD iCAD
$19.96 /

+0.04 (+0.20%)

GBOX GreenBox
$15.36 /

+1.47 (+10.58%)

DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

ARES Ares Management
$59.12 /

+1.59 (+2.76%)

ICAD iCAD
$19.96 /

+0.04 (+0.20%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
ILMN Illumina
$384.41 /

-0.72 (-0.19%)

04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
03/31/21 Canaccord
Canaccord upgrades Illumina, says worth owning with or without Grail
03/31/21 Canaccord
Illumina upgraded to Buy from Hold at Canaccord
03/31/21 Atlantic Equities
Illumina downgraded to Neutral from Overweight at Atlantic Equities
SPNE SeaSpine
$17.93 /

+0.23 (+1.30%)

03/24/21 Canaccord
Canaccord likes what 7D acquisition brings to SeaSpine Holdings
03/02/21 Canaccord
SeaSpine price target raised to $25 from $23 at Canaccord
03/01/21 Piper Sandler
SeaSpine price target raised to $28 from $22 at Piper Sandler
01/29/21 Piper Sandler
SeaSpine price target raised to $22 from $18 at Piper Sandler
DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

01/13/21 Goldman Sachs
Sapiens initiated with a Neutral at Goldman Sachs
10/21/20 RBC Capital
Duck Creek Technologies price target raised to $51 from $45 at RBC Capital
10/21/20 Barclays
Duck Creek Technologies price target raised to $48 from $43 at Barclays
09/08/20 DA Davidson
Duck Creek Technologies initiated with a Buy at DA Davidson
GBOX GreenBox
$15.36 /

+1.47 (+10.58%)

OPNT Opiant Pharmaceuticals
$11.15 /

+0.49 (+4.60%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

03/03/21 Morgan Stanley
Maravai Lifesciences price target raised to $54 from $35 at Morgan Stanley
03/03/21 KeyBanc
Maravai Lifesciences price target raised to $46 from $39 at KeyBanc
03/03/21 Credit Suisse
Maravai Lifesciences price target raised to $42 from $34 at Credit Suisse
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

04/01/21
Fly Intel: Top five analyst downgrades
04/01/21 Piper Sandler
Phillips 66 downgraded to Neutral on valuation at Piper Sandler
04/01/21 Piper Sandler
Phillips 66 downgraded to Neutral from Overweight at Piper Sandler
03/17/21 Citi
Phillips 66 price target raised to $99 from $81 at Citi
ARES Ares Management
$59.12 /

+1.59 (+2.76%)

03/29/21
Fly Intel: Top five analyst downgrades
03/29/21 BMO Capital
Ares Management downgraded to Market Perform from Outperform at BMO Capital
02/24/21 Credit Suisse
Ares Management re-initiated with a Neutral at Credit Suisse
02/12/21 Barclays
Ares Management price target raised to $58 from $56 at Barclays
TPTX Turning Point Therapeutics
$89.91 /

-0.7 (-0.77%)

03/02/21 Roth Capital
Turning Point has 'many value-driving catalysts' in 2021, says Roth Capital
02/02/21 Canaccord
Turning Point Therapeutics price target raised to $145 from $122 at Canaccord
01/29/21 Roth Capital
Turning Point Therapeutics price target raised to $170 from $140 at Roth Capital
01/19/21 H.C. Wainwright
Turning Point Therapeutics price target raised to $190 from $130 at H.C. Wainwright
UCTT Ultra Clean
$64.92 /

+1.37 (+2.16%)

02/18/21 Needham
Ultra Clean price target raised to $55 from $43 at Needham
02/18/21 Craig-Hallum
Ultra Clean price target raised to $69 from $47 at Craig-Hallum
01/29/21 Cowen
Cowen upgrades Ultra Clean to Outperform on robust spending trends
01/29/21 Cowen
Ultra Clean upgraded to Outperform from Market Perform at Cowen
USAT USA Technologies
$12.77 /

+0.76 (+6.33%)

02/05/21 Lake Street
USA Technologies price target raised to $12 from $10 at Lake Street
01/06/21 Northland
USA Technologies named a top pick for 2021 at Northland
12/16/20 Northland
Northland upgrades 'recovery story' USA Technologies to Outperform
12/16/20 Northland
USA Technologies upgraded to Outperform from Market Perform at Northland
USAT USA Technologies
$12.77 /

+0.76 (+6.33%)

UCTT Ultra Clean
$64.92 /

+1.37 (+2.16%)

TPTX Turning Point Therapeutics
$89.91 /

-0.7 (-0.77%)

SPNE SeaSpine
$17.93 /

+0.23 (+1.30%)

PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

OPNT Opiant Pharmaceuticals
$11.15 /

+0.49 (+4.60%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

ICAD iCAD
$19.96 /

+0.04 (+0.20%)

DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

ARES Ares Management
$59.12 /

+1.59 (+2.76%)

  • 09
    Apr
  • 08
    Apr
  • 06
    Apr
  • 03
    Mar
  • 17
    Feb
  • 29
    Jan
  • 20
    Nov
  • 11
    Nov
  • 27
    Oct
  • 14
    Aug
  • 19
    May
PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

USAT USA Technologies
$12.77 /

+0.76 (+6.33%)

UCTT Ultra Clean
$64.92 /

+1.37 (+2.16%)

SPNE SeaSpine
$17.93 /

+0.23 (+1.30%)

OPNT Opiant Pharmaceuticals
$11.15 /

+0.49 (+4.60%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

ICAD iCAD
$19.96 /

+0.04 (+0.20%)

DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

ARES Ares Management
$59.12 /

+1.59 (+2.76%)

USAT USA Technologies
$12.77 /

+0.76 (+6.33%)

PSX Phillips 66
$82.06 /

-1.08 (-1.30%)

MRVI Maravai Lifesciences
$34.59 /

+0.4 (+1.17%)

ILMN Illumina
$384.41 /

-0.72 (-0.19%)

DCT Duck Creek Technologies
$44.50 /

-0.5 (-1.11%)

Hot Stocks
Opiant says 1st patients dosed in comparing Nalmefene, with nasal Naloxone » 16:06
04/05/21
04/05
16:06
04/05/21
16:06
OPNT

Opiant Pharmaceuticals

$11.11 /

+0.45 (+4.22%)

Opiant Pharmaceuticals…

Opiant Pharmaceuticals announced that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with nasal naloxone. The single-center, randomized, open-label study in heathy volunteers will evaluate the effectiveness of 3mg nasal nalmefene, in comparison to 4 mg nasal naloxone, to reverse the respiratory depression produced by the synthetic opioid, remifentanil. Details of this clinical trial can be found listed on www.clinicaltrials.gov. Identifier: NCT04828005. An overdose can be fatal when an opioid interrupts the body's natural drive to breathe. Top-line data from the trial are expected in the fourth quarter 2021. According to provisional data from the Centers for Disease Control and Prevention, CDC, more than 63,000 opioid overdose deaths were recorded in the United States during the 12 months ending August 2020 - a 31% increase to the prior year and record high. The most common are overdoses from synthetic opioids, such as illicitly manufactured fentanyl, which is 50x more potent than heroin. "The initiation of this head-to-head study is an important step in our comprehensive development program for OPNT003, nasal nalmefene," said Dr. Roger Crystal, President and CEO, Opiant Pharmaceuticals. "The potential for a faster acting, longer duration antagonist holds promise in the fight against an increasing number of opioid overdoses that have been driven by more powerful synthetic opioids, such as fentanyl.

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$11.11 /

+0.45 (+4.22%)

OPNT Opiant Pharmaceuticals
$11.11 /

+0.45 (+4.22%)

OPNT Opiant Pharmaceuticals
$11.11 /

+0.45 (+4.22%)

Hot Stocks
Opiant Pharmaceuticals awarded final tranche of $1.8M from NIDA » 16:07
03/31/21
03/31
16:07
03/31/21
16:07
OPNT

Opiant Pharmaceuticals

$10.29 /

-0.25 (-2.37%)

Opiant Pharmaceuticals…

Opiant Pharmaceuticals has been awarded the third and final tranche of $1.8M from the total grant of approximately $7.4M from the National Institute on Drug Abuse, part of the National Institutes of Health to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose. The grant was awarded under award number 5U01DA046093-03. With the substantial increase in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving synthetic opioids, including illicitly manufactured fentanyl1, NIH leadership has highlighted the need for stronger, longer-acting formulations of antagonists to help prevent overdose deaths. "The award of the final tranche of NIDA's grant validates the progress we are making to develop OPNT003 for submission to the FDA," said Roger Crystal, M.D., President and CEO, Opiant Pharmaceuticals. "If approved, we believe OPNT003 can make a meaningful contribution to the NIH strategy identifying scientific solutions and novel pharmacotherapies to save lives from opioid overdose, particularly in the face of more powerful and potentially dangerous synthetic opioids, such as fentanyl."

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$10.29 /

-0.25 (-2.37%)

OPNT Opiant Pharmaceuticals
$10.29 /

-0.25 (-2.37%)

OPNT Opiant Pharmaceuticals
$10.29 /

-0.25 (-2.37%)

Over a month ago
Earnings
Opiant Pharmaceuticals reports Q4 EPS (16c), consensus 7c » 16:42
03/04/21
03/04
16:42
03/04/21
16:42
OPNT

Opiant Pharmaceuticals

$12.25 /

-0.82 (-6.27%)

Reports Q4 revenue…

Reports Q4 revenue $9.92M, consensus $9.2M. Commenting, Roger Crystal, president and CEO of Opiant, said: "We are excited to start 2021 by announcing important clinical progress with OPNT003, nasal nalmefene, for opioid overdose. We are nearing completion of our confirmatory PK study and intend to begin our PD study mid-March. Importantly, we expect top-line data from both of these studies later this year, and we remain on track to complete our NDA for the use of OPNT003 in opioid overdose for FDA review by the end of 2021. Opioid overdose continues to be a growing and devastating epidemic in need of effective treatment solutions. Opiant's purpose - to develop new medicines to treat addictions and drug overdose - has never been more relevant."

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$12.25 /

-0.82 (-6.27%)

OPNT Opiant Pharmaceuticals
$12.25 /

-0.82 (-6.27%)

OPNT Opiant Pharmaceuticals
$12.25 /

-0.82 (-6.27%)

Hot Stocks
Opiant says First patient dosed in confirmatory PK study of PNT003 » 16:19
02/08/21
02/08
16:19
02/08/21
16:19
OPNT

Opiant Pharmaceuticals

$13.25 /

+0.25 (+1.92%)

Opiant Pharmaceuticals,…

Opiant Pharmaceuticals, announced the dosing of the first patient in a confirmatory pharmacokinetic study for PNT003, nasal nalmefene, for the treatment of opioid overdose. Results from the study are anticipated June 2021. Deaths resulting from opioid overdose are at record levels, driven in large part by high-potency synthetic opioids, such as fentanyl. In 2017, the National Institutes of Health's ("NIH") leadership called for longer lasting and stronger opioid overdose reversal agents in response to this escalating public health crisis(1).

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$13.25 /

+0.25 (+1.92%)

OPNT Opiant Pharmaceuticals
$13.25 /

+0.25 (+1.92%)

OPNT Opiant Pharmaceuticals
$13.25 /

+0.25 (+1.92%)

Over a quarter ago
Syndicate
Opiant Pharmaceuticals files to sell 1.27M shares of common stock for holders  16:10
01/11/21
01/11
16:10
01/11/21
16:10
OPNT

Opiant Pharmaceuticals

$8.55 /

+0.1 (+1.18%)

 
ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$8.55 /

+0.1 (+1.18%)

OPNT Opiant Pharmaceuticals
$8.55 /

+0.1 (+1.18%)

OPNT Opiant Pharmaceuticals
$8.55 /

+0.1 (+1.18%)

On The Fly
Fly Intel: After-Hours Movers » 18:41
12/14/20
12/14
18:41
12/14/20
18:41
OPNT

Opiant Pharmaceuticals

$8.47 /

+0.25 (+3.04%)

, MDWD

MediWound

$3.65 /

+0.03 (+0.83%)

, IVAC

Intevac

$6.45 /

-0.05 (-0.77%)

, MESO

Mesoblast

$16.85 /

-0.21 (-1.23%)

, EAF

GrafTech

$9.65 /

-0.14 (-1.43%)

, OCUL

Ocular Therapeutix

$22.31 /

+1.57 (+7.57%)

Check out this evening's…

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$8.47 /

+0.25 (+3.04%)

OCUL Ocular Therapeutix
$22.31 /

+1.57 (+7.57%)

MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

MDWD MediWound
$3.65 /

+0.03 (+0.83%)

IVAC Intevac
$6.45 /

-0.05 (-0.77%)

EAF GrafTech
$9.65 /

-0.14 (-1.43%)

OPNT Opiant Pharmaceuticals
$8.47 /

+0.25 (+3.04%)

MDWD MediWound
$3.65 /

+0.03 (+0.83%)

10/19/20 BTIG
Vericel price target raised to $30 from $23 at BTIG
09/23/20
Fly Intel: Top five analyst initiations
09/23/20 BTIG
MediWound initiated with a Buy at BTIG
IVAC Intevac
$6.45 /

-0.05 (-0.77%)

08/31/20 Northland
Intevac initiated with an Outperform at Northland
03/19/20 B. Riley
B. Riley FBR downgrades 10 Semiconductor names on escalating risks
03/19/20 B. Riley
Intevac downgraded to Neutral from Buy at B. Riley FBR
MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

12/04/20
Fly Intel: Top five analyst downgrades
12/04/20 Chardan
Mesoblast downgraded to Sell from Neutral at Chardan
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 RBC Capital
Mesoblast initiated with a Sector Perform at RBC Capital
EAF GrafTech
$9.65 /

-0.14 (-1.43%)

02/13/20 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
02/13/20 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
12/17/19 BMO Capital
GrafTech downgraded to Market Perform from Outperform at BMO Capital
OCUL Ocular Therapeutix
$22.31 /

+1.57 (+7.57%)

11/13/20 Raymond James
Ocular Therapeutix price target raised to $25 from $15 at Raymond James
11/11/20 Piper Sandler
Piper says Ocular data 'very much supportive' of plans to advance OTX-TKI
11/06/20 H.C. Wainwright
Ocular Therapeutix price target raised to $14 from $13 at H.C. Wainwright
11/05/20 Piper Sandler
Ocular Therapeutix price target raised to $16 from $14 at Piper Sandler
OPNT Opiant Pharmaceuticals
$8.47 /

+0.25 (+3.04%)

OCUL Ocular Therapeutix
$22.31 /

+1.57 (+7.57%)

MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

MDWD MediWound
$3.65 /

+0.03 (+0.83%)

IVAC Intevac
$6.45 /

-0.05 (-0.77%)

EAF GrafTech
$9.65 /

-0.14 (-1.43%)

  • 16
    Dec
  • 14
    Oct
  • 20
    May
OCUL Ocular Therapeutix
$22.31 /

+1.57 (+7.57%)

MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

IVAC Intevac
$6.45 /

-0.05 (-0.77%)

MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

Hot Stocks
Opiant announces additional commitment of up to $3.5M from BARDA » 16:06
12/14/20
12/14
16:06
12/14/20
16:06
OPNT

Opiant Pharmaceuticals

$8.47 /

+0.25 (+3.04%)

Opiant Pharmaceuticals …

Opiant Pharmaceuticals announced an additional commitment of up to $3.5M from the Biomedical Advanced Research and Development Authority or BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increases the total potential value of the BARDA contract to $8.1M. "We thank BARDA for their ongoing support of OPNT003, nasal nalmefene," said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. "We believe OPNT003, nasal nalmefene, has the potential to be a best-in-class rescue agent for preventing opioid overdose deaths, particularly from synthetic opioids like fentanyl. We remain on track to file a New Drug Application with the U.S. Food and Drug Administration by the end of 2021." An earlier award from BARDA for up to $4.6M, combined with a $7.4M grant Opiant received from the National Institute on Drug Abuse , also supports the clinical development and U.S. regulatory submission of OPNT003. The additional BARDA support will fund both a planned pharmacodynamic study in healthy volunteers and development work associated with the use of Aptar Pharma's Unit Dose System.

ShowHide Related Items >><<
OPNT Opiant Pharmaceuticals
$8.47 /

+0.25 (+3.04%)

OPNT Opiant Pharmaceuticals
$8.47 /

+0.25 (+3.04%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/19/20
11/19
04:55
11/19/20
04:55
MRNA

Moderna

$88.90 /

-4.225 (-4.54%)

, IMGN

ImmunoGen

$5.75 /

-0.035 (-0.61%)

, ESPR

Esperion

$29.18 /

-0.95 (-3.15%)

, CRL

Charles River

$234.11 /

-2.205 (-0.93%)

, AXGN

AxoGen

$15.16 /

-0.05 (-0.33%)

, INMD

InMode

$42.75 /

+0.16 (+0.38%)

, PRTA

Prothena

$12.10 /

-0.24 (-1.94%)

, SYNH

Syneos Health

$63.21 /

-0.24 (-0.38%)

, RDNT

RadNet

$18.19 /

-0.75 (-3.96%)

, OPNT

Opiant Pharmaceuticals

$7.95 /

+0.2 (+2.58%)

, FGEN

FibroGen

$41.56 /

-2.58 (-5.85%)

, MGLN

Magellan Health

$82.25 /

-2.47 (-2.92%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.66 /

-0.53 (-3.27%)

, IVA

Inventiva

$14.00 /

+ (+0.00%)

, ITOS

iTeos Therapeutics

$25.09 /

+1.14 (+4.76%)

, CLBS

Caladrius

$1.44 /

-0.055 (-3.68%)

, ALNA

Allena Pharmaceuticals

$1.37 /

-0.07 (-4.86%)

, SEEL

Seelos Therapeutics

$0.78 /

-0.0296 (-3.65%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$10.82 /

-0.23 (-2.08%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$29.18 /

-0.95 (-3.15%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$234.11 /

-2.205 (-0.93%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.75 /

+0.16 (+0.38%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.10 /

-0.24 (-1.94%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.19 /

-0.75 (-3.96%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+ (+0.00%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

10/01/20 B. Riley
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/18/20
11/18
04:55
11/18/20
04:55
MRNA

Moderna

$93.12 /

-4.88 (-4.98%)

, IMGN

ImmunoGen

$5.78 /

+0.03 (+0.52%)

, ESPR

Esperion

$30.13 /

+0.02 (+0.07%)

, CRL

Charles River

$236.30 /

-1.56 (-0.66%)

, AXGN

AxoGen

$15.29 /

+0.18 (+1.19%)

, INMD

InMode

$42.61 /

+0.8 (+1.91%)

, PRTA

Prothena

$12.34 /

-0.03 (-0.24%)

, SYNH

Syneos Health

$63.45 /

-0.37 (-0.58%)

, RDNT

RadNet

$18.94 /

-0.05 (-0.26%)

, OPNT

Opiant Pharmaceuticals

$7.78 /

-0.02 (-0.26%)

, FGEN

FibroGen

$44.14 /

+1.12 (+2.60%)

, MGLN

Magellan Health

$84.72 /

-0.64 (-0.75%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$16.19 /

+0.5 (+3.19%)

, IVA

Inventiva

$14.00 /

+0.175 (+1.27%)

, ITOS

iTeos Therapeutics

$23.95 /

-0.08 (-0.33%)

, CLBS

Caladrius

$1.50 /

-0.005 (-0.33%)

, ALNA

Allena Pharmaceuticals

$1.43 /

-0.15 (-9.49%)

, SEEL

Seelos Therapeutics

$0.81 /

-0.0119 (-1.45%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.04 /

+0.03 (+0.27%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.13 /

+0.02 (+0.07%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$236.30 /

-1.56 (-0.66%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.61 /

+0.8 (+1.91%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.34 /

-0.03 (-0.24%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.94 /

-0.05 (-0.26%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+0.175 (+1.27%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

10/01/20 B. Riley
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.